Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

Details

Language :

English

ISSN :

20959907

Volume :

9

Issue :

1

Database :

Complementary Index

Journal :

Signal Transduction & Targeted Therapy

Publication Type :

Academic Journal

Accession number :

178969114

Full Text :

https://doi.org/10.1038/s41392-024-01927-9